SynthesisFrontiers in immunology2023
Meta-analysis of neoadjuvant immunotherapy for non-metastatic colorectal cancer.
Synthesis in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 3 syntheses or guidelines pooled it, 22 citations in OpenAlex.
- Acute leukemia during pregnancy: a single center experience with 23 cases, 2012-2022 and literature review.Annals of medicine · 2026Pooled it
- The neoadjuvant immunotherapy for non-metastatic mismatch repair-deficient colorectal cancer: a systematic review.Frontiers in immunology · 2025Pooled it
- Impact of exercise type, duration, and intensity on depressive symptoms in older adults: a systematic review and meta-analysis.Frontiers in psychology · 2024Pooled it
- Predictive value of NRI, NLR, PLR and LMR for therapeutic efficacy and prognosis in advanced rectal cancer patients treated with PD-1/PD-L1 immunotherapy.Frontiers in surgery · 2026Article
- Functional outcomes in rectal cancer patients treated with immunotherapy and neoadjuvant therapy: a retrospective analysis.Langenbeck's archives of surgery · 2025Article
- Current and future perspectives in the management and treatment of colorectal cancer.World journal of clinical oncology · 2025Article
- Towards the Prediction of Responses to Cancer Immunotherapy: A Multi-Omics Review.Life (Basel, Switzerland) · 2025Review
- Colorectal Cancer: Risk Factors, Novel Approaches in Molecular Screening and Treatment.International journal of molecular and cellular medicine · 2025Review
- Impact of body composition on pathological response to neoadjuvant immunotherapy in dMMR/MSI-H colorectal cancer.Frontiers in immunology · 2025Article
- Immune activation following PD-L1 inhibitor plus chemoradiotherapy in locally advanced rectal cancer: a retrospective, single-arm study.Frontiers in immunology · 2025Article
- Neoadjuvant immunotherapy leads to complete pathologic response in locally advanced colon cancer.Clinical case reports · 2024Article
- Establishment of a chemokine-based prognostic model and identification of CXCL10+ M1 macrophages as predictors of neoadjuvant therapy efficacy in colorectal cancer.Frontiers in immunology · 2024Article
- A management of patients achieving clinical complete response after neoadjuvant therapy and perspectives: on locally advanced rectal cancer.Frontiers in oncology · 2024Review
- Safety and feasibility of minimally invasive gastrectomy after neoadjuvant immunotherapy for locally advanced gastric cancer: a propensity score-matched analysis in China.Gastroenterology report · 2024Article
- Immunotherapy for Colorectal Cancer with High Microsatellite Instability: The Ongoing Search for Biomarkers.Cancers · 2023Review
- Neoadjuvant Immunotherapy for Patients with dMMR/MSI-High Gastrointestinal Cancers: A Changing Paradigm.Cancers · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immunotherapy has been approved for the treatment of metastatic colorectal cancer. The efficacy and safety of neoadjuvant immunotherapy for the treatment of non-metastatic colorectal cancer remains unclear. We tried to explore clinical effect of neoadjuvant immunotherapy in the treatment of non-metastatic colorectal cancer. Methods: We searched the databases (PubMed, Wanfang Embase, Cochrane Library and China National Knowledge Infrastructure databases) to obtain suitable articles up to September 2022. The primary outcomes of pathological complete response (pCRs), major pathological response (MPR), objective response rate (ORR), R0-resection and anus preserving rate were collected and evaluated. Secordary outcomes (pCRs and MPR) of subgroup analysis between deficient mismatch repair/microsatellite instability-high group (dMMR/MSI-H) and proficient mismatch repair/microsatellite stable group (pMMR/MSS) and outcomes for rectal cancer were analyzed for the final results. Results: We included ten articles and 410 cases of non-metastatic colorectal cancer with neoadjuvant immunotherapy. There were 113 (27.5%) cases with the dMMR/MSI-H status and 167 (40.7%) cases with the pMMR/MSS status. pCRs was found in 167/373 (44.6%) patients (ES: 0.49, 95% CI: 0.36 to 0.62, Conclusion: Neoadjuvant immunotherapy could increase pCRs and MPR rate for non-metastatic colorectal cancer. Neoadjuvant immunotherapy could achieve better pCRs rate in dMMR/MSI-H group than in the pMMR/MSS group. Neoadjuvant immunotherapy could be another treatment option for non-metastatic colorectal cancer. Systematic review registration: https://www.crd.york.ac.uk/prospero/#myprospero, identifier CRD42022350523.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.